The Interaction between the Immune System and Epigenetics in the Etiology of Autism Spectrum Disorders by Stefano Nardone & Evan Elliott
REVIEW
published: 12 July 2016
doi: 10.3389/fnins.2016.00329
Frontiers in Neuroscience | www.frontiersin.org 1 July 2016 | Volume 10 | Article 329
Edited by:
Benjamin Gesundheit,
Cell El Ltd., Israel
Reviewed by:
Anthony John Hannan,
University of Melbourne, Australia
Hansen Wang,
University of Toronto, Canada
*Correspondence:
Evan Elliott
evan.elliott@biu.ac.il
Specialty section:
This article was submitted to
Child and Adolescent Psychiatry,
a section of the journal
Frontiers in Neuroscience
Received: 02 May 2016
Accepted: 29 June 2016
Published: 12 July 2016
Citation:
Nardone S and Elliott E (2016) The
Interaction between the Immune
System and Epigenetics in the
Etiology of Autism Spectrum
Disorders. Front. Neurosci. 10:329.
doi: 10.3389/fnins.2016.00329
The Interaction between the Immune
System and Epigenetics in the
Etiology of Autism Spectrum
Disorders
Stefano Nardone and Evan Elliott *
Faculty of Medicine, Bar Ilan University, Safed, Israel
Recent studies have firmly established that the etiology of autism includes both genetic
and environmental components. However, we are only just beginning to elucidate the
environmental factors that might be involved in the development of autism, as well
as the molecular mechanisms through which they function. Mounting epidemiological
and biological evidence suggest that prenatal factors that induce a more activated
immune state in the mother are involved in the development of autism. In parallel,
molecular studies have highlighted the role of epigenetics in brain development as a
process susceptible to environmental influences and potentially causative of autism
spectrum disorders (ASD). In this review, we will discuss converging evidence for a
multidirectional interaction between immune system activation in the mother during
pregnancy and epigenetic regulation in the brain of the fetus that may cooperate to
produce an autistic phenotype. This interaction includes immune factor-induced changes
in epigenetic signatures in the brain, dysregulation of epigenetic modifications specifically
in genomic regions that encode immune functions, and aberrant epigenetic regulation of
microglia. Overall, the interaction between immune system activation in the mother and
the subsequent epigenetic dysregulation in the developing fetal brain may be a main
consideration for the environmental factors that cause autism.
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INVOLVEMENT OF MATERNAL IMMUNE ACTIVATION IN AUTISM
The etiology of autism spectrum disorders (ASD) is widely defined by the interaction between
genetics and environmental factors. Within the past two decades, a large number of resources
have been invested in understanding the genetic underpinnings of ASD. Several large scale genetic
studies have uncovered single nucleotide variations (SNVs; Gaugler et al., 2014; De Rubeis and
Buxbaum, 2015; LoParo and Waldman, 2015), copy-number variations (CNVs) (Shishido et al.,
2014) and de novomutations (De Rubeis et al., 2014a; Iossifov et al., 2014) that are associated with
ASD risk. Recent studies have found that common genetic variations account for a high percentage
of the genetic risk for ASD (Gaugler et al., 2014). Of particular importance in this current
discussion, the genetic variations associated with autism are also often present in individuals
without an ASD diagnosis. One investigation reported that the presence of autism-risk alleles
in individuals that are not diagnosed with ASD was associated with a higher IQ (Clarke et al.,
2016), while another study found that genetic risk for ASD is associated with changes in social
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behavior even in individuals without an ASD diagnosis
(Robinson et al., 2016). Overall, these studies highlight the fact
that genetic risk for autism can influence multiple aspects of
behavior, but it is often not sufficient to induce the full spectrum
of behavior needed for a diagnosis of ASD. Therefore, a genetic
contribution is likely to introduce a predisposition to develop
ASD, while its actual onset requires a further environment
agitation.
Current studies have been exploring the possible
environmental factors that may be involved in the etiology
of ASD. An expanding list includes viral infection and exposure
to environmental toxins during pregnancy, gestational diabetes,
among others (Grabrucker, 2012). In particular, compounding
evidence supports a role for immune system activation at specific
time frames in the pregnant mother as a risk factor for autism
(Table 1). The first evidence for this connection was provided
from the Rubella outbreak of the 1960s. Autism was diagnosed
in ∼5–10% of children born to mothers that were infected by
Rubella virus (Chess, 1971, 1977; Hutton, 2016). Subsequently,
a study, surveying Danish births from 1980 to 2005 determined
a three-fold increase in the incidence of ASD in children whose
mothers were hospitalized for viral infection, specifically during
the first trimester of pregnancy (Atladóttir et al., 2010). A report
of Swedish births found a 30% increase in ASDwhen the mothers
were hospitalized for viral infections during pregnancy (Lee
et al., 2014). However, unlike the Danish study, this investigation
reported a significant effect for an association between ASD
diagnosis and viral infection in all three trimesters.
Additional support for the role of maternal immune activation
(MIA) in the development of autism has come from animal
experimentation. MIA can be simulated by injecting pregnant
rodents with Poly I:C, a synthetic double-stranded mimetic
of the RNA molecule, which triggers an immune response
through the activation of Toll like Receptor 3, and subsequent
expression of interferon-1 (Alexopoulou et al., 2001). This
process induces activation of both innate and adaptive immune
regulatory mechanisms in the pregnant rodent female. Offspring
can then be tested for behavioral abnormalities and changes in
neurodevelopment. Malvoka et al. determined that the offspring
of pregnant mice treated with Poly I:C displayed all the core
deficits associated with ASD including problems in social,
communication, and repetitive behaviors (Malkova et al., 2012).
Several follow up studies verified these findings and went on
to suggest other related deficits in neurodevelopment that are
responsible for this behavior (Smith et al., 2007; Canetta et al.,
2016; Choi et al., 2016). In addition to rodent models, MIA
has recently been induced in monkeys. Offspring of Rhesus
monkeys subjected to MIA displayed deficits in social behavior
and an increase in repetitive behaviors (Bauman et al., 2014;
Machado et al., 2015). Therefore, both epidemiological and
animal modeling studies support a causative role for MIA in the
etiology of ASD.
Other studies have shown another possible trigger of an
immunity-induced autism phenotype could be due to the
presence of an autoimmune disorder in the mother. A study of
the Swedish health registry uncovered an increase of 60% in the
odds for developing autism among those children of mothers
diagnosed with an autoimmune disorder (Keil et al., 2010).
Interestingly, an increase of 40% was detected among children
whose fathers had an autoimmune disorder. A separate study
in Northern California found an association between maternal
psoriasis and the insurgence of autism, although the association
between autoimmune diseases in general and autism was not
significant (Croen et al., 2005). In a large study examining
nearly 700,000 Swedish births, Atladottir et al. found that autism
was associated with maternal Rheumatoid Arthritis and Celiac
Disease, as well as those with a family history of Type 1 Diabetes
(Atladóttir et al., 2009). An increase in autism was also identified
in a cohort of Canadian children from mothers with Systemic
Lupus Erythematosus (Vinet et al., 2015). A recent meta-analysis
of studies performed inmultiple locations confirmed a significant
association between maternal autoimmune diseases and ASD
(Chen et al., 2016). Generally, it has become apparent that both
MIA and maternal autoimmune disease are associated with ASD.
EPIGENETICS IN AUTISM
Epigenetics is responsible for the proper development of the
nervous system and is highly regulated by environmental
factors, such as an inflammatory response (Jirtle and Skinner,
2007). Epigenetics refers to heritable changes in gene regulatory
mechanisms that are independent from alteration of the
underlying DNA sequence. Two of the most commonly studied
epigenetic markers include DNA methylation and histone
modifications (Jones, 2001; Goldberg et al., 2007). Both markers
influence the establishment of gene transcription patterns
through multiple mechanisms, including the regulation of
genomic, structure, and the accessibility of genomic loci to
diverse regulatory factors (e.g., transcription factors, enhancers,
silencers). Temporal changes in epigenetic signature during the
developmental stage finely tunes the differentiation of precursor
cells into their specific mature state (Kiefer, 2007). Therefore,
epigenetic markers display a relatively high level of plasticity
during periods of cellular specification, including in brain
development (Spiers et al., 2015). As such, it is likely that
environmental disturbances during pregnancy may induce stable
and long-term modifications in epigenetic patterns that probably
survive until adulthood.
Genetic studies demonstrated preliminary evidence of a role
for epigenetic mechanisms in the etiology of ASD. Analysis of
hundreds of genes associated with ASD reveal enrichment for
two biological functions: synaptic plasticity or chromatin binding
factors (Lasalle, 2013; De Rubeis et al., 2014b). The enrichment
of chromatin binding genes in autism studies suggests their
potential role in the etiology of ASD. Rett Syndrome is one
very well-known example of a genetic neurodevelopmental
condition that includes autistic behavior, and whose etiology
is directly related to epigenetic regulation. Rett Syndrome is
caused by mutations in the gene MECP2, which encodes for the
methylated DNA binding protein MeCP2 (Amir et al., 1999).
Upon binding methylated DNA, MeCP2 either activates or
inhibits gene transcription depending on the genomic context
(Chahrour et al., 2008). The fact that mutations in the MECP2
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TABLE 1 | Main manuscripts that investigated the association between MIA and autism, epigenetic changes in the autism postmortem brain, or
MIA-induced changes in brain epigenetic patterns in mouse models.
Geographic region Association with autism References
MATERNAL IMMUNE ACTIVATION IN ASD-EPIDEMIOLOGICAL STUDIES
United States Positive association with Congenital rubella syndrome Chess, 1977
Denmark Positive association with hospitalization for viral infections in first trimester and bacterial infections in
second trimester
Atladóttir et al., 2010
Sweden Positive association with hospitalization for viral infections in all three trimesters Lee et al., 2014
Sweden Positive association with maternal autoimmune disease in general. In addition, association with maternal
Myasthenia Gravis and Rheumatic Fever
Keil et al., 2010
United States, CA No association with maternal autoimmune diseases in general. Positive association with maternal
psoriasis
Croen et al., 2005
Denmark Positive association with maternal Rheumatoid Arthritis, Celiac Disease, and Type1 Diabetes Atladóttir et al., 2009
Canada Positive association with Systemic Lupus Erythematosus Vinet et al., 2015
Brain Area Method Main differences between control and autism
cohorts
References
EPIGENETIC CHANGES IN ASD BRAIN-POSTMORTEM STUDIES
Frontal cortex, temporal
cortex and cerebellum
Genome-wide 450K Illumina BeadArray Hypomethylation in PRRT1 and C11orf21;
Hypermethylation in ZFP57 and SDHAP3
Ladd-Acosta et al., 2014
Frontal and cingulate cortex Genome-wide 450K Illumina BeadArray Hypomethylation in genes implicated in immune
response. Hypermethylation in genes implicated in
synaptic processes
Nardone et al., 2014
Cerebellum and occipital
cortex
Genome-wide 27K Illumina BeadArray No significant differences Ginsberg et al., 2012
Cerebellum and cortex Gene-specific sodium bisulfite sequencing Hypermethylation in Shank3 Zhu et al., 2014
Temporal cortex Gene-specific sodium bisulfite sequencing Hypermethylation in RELN Lintas et al., 2016
Cerebellum Methylation-sensitive PCR; Chip-real time PCR Hypermethylation and increased H3K27me3 in EN-2
gene; global DNA hypermethytation
James et al., 2013
Cerebellum hMeDIP-real time PCR; Chip-real time PCR Hyperhydroxymethylation and decreased MeCP2
binding In EN-2 gene promoter
James et al., 2014
Frontal cortex H3K4me3 Chip-seq on FACS-sorted neuronal
nuclei
No significant differences; subset of autism cases
displays spreading of H3K4me3 from transcription start
sites to adjacent regions
Shulha et al., 2012
Brain area Method Main findings References
MIA-INDUCED EPIGENETIC CHANGES IN BRAIN-RODENT STUDIES
Hypothalamus Gene-specific sodium bisulfite sequencing Decrease in MECP2 and LINE1 methylation Basil et al., 2014
Frontal cortex Gene-specific sodium bisulfite sequencing Increase in GAD1 and GAD2 methylation Labouesse et al., 2015
Frontal cortex and
hippocampus
Western blot; Chip-real time PCR Global histone hypoacetylation in the cortex of juvenile
offspring; promoter-specific hypoacetylation in adult
cortex and hyperacetylation in adult hippocampus
Tang et al., 2013
Frontal cortex Chip-seq No significant changes in H3K4me3 marks Connor et al., 2012
gene induce a syndrome with autistic-like behavior, indicates a
direct link between DNA methylation-regulated gene expression
and ASD symptomatology. Other chromosome binding genes
that have been found to be strongly associated with ASD include
CHD8, MBD5, and AUTS2 (Sultana et al., 2002; Cukier et al.,
2012; Bernier et al., 2014). Therefore, genetic studies have long
proposed an involvement of epigenetics in the etiology of ASD.
While genetic studies have provided preliminary evidence
for the involvement of epigenetics in the etiology of ASD,
epigenetic-based studies were necessary to finally prove a direct
association between dysregulation of epigenetic signatures, both
in peripheral tissues and the brain, and ASD (Ciernia and LaSalle,
2016). Post-mortem brain epigenetic studies have been critical
in understanding how epigenetic patterns may be affected in
the ASD brain. This is due to the fact that each tissue and cell
type are characterized by highly specific epigenetic signatures.
Accordingly, the interrogation of peripheral tissues may not truly
represent changes seen in brain tissues. Previous reviews have
thoroughly discussed the literature on epigenetic dysregulation in
ASD, including the periphery (Tordjman et al., 2014; Loke et al.,
2015; Ciernia and LaSalle, 2016). Here, we will focus specifically
on epigenetic dysregulation in the brain, in order to later discuss
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the possible role of MIA in brain epigenetics and development
of ASD (Table 1).
Several gene-specific studies have been performed to provide
preliminary evidence of DNA methylation dysregulation in the
ASD brain. An initial study analyzed the DNA methylation
profile of the autism-related gene Shank3. This study determined
a hypermethylation of multiple intragenic regions in the Shank3
gene (Zhu et al., 2014). While mutations in Shank3 may be found
in ∼0.5% of individuals with autism, this study suggests that
epigenetic changes in Shank3 may actually be more widespread.
Therefore, epigenetic alterations may significantly affect the
function of autism-related genes in the absence of those rare
genetic changes. Other studies have also determined dysregulated
DNA methylation signatures in the autism-related genes RELN
and EN-2 (James et al., 2013, 2014; Lintas et al., 2016).
To date, only a few epigenetic studies have investigated in
a genome-wide fashion the DNA methylation profile of post-
mortem brain tissue from individuals with ASD diagnosis and
matched controls. These studies have been performed using the
Illumina 450K BeadArray, which profiles the methylation level
of ∼480,000 CpGs throughout the entire human genome. Using
this method, Ladd Acosta et al. discovered four differentially
methylated regions in the DNA when comparing the control
and autism groups (Ladd-Acosta et al., 2014). These methylated
regions containing multiple CpGs included the genes PRRT1,
ZFP57, and TSPAN32 in the cortex, and SDHAP3 in the
cerebellum. In a separate study, we found that over 5000
individual CpGs were differentially methylated in the frontal
cortex when comparing the control and autism cohorts (Nardone
et al., 2014). Hypermethylated and hypomethylated CpGs were
mainly found in genomic regions that were associated to
genes enriched with synaptic functions and immune response,
respectively. Of interest, the gene TSPAN32 had about an 8%
decrease in DNAmethylation levels in the ASD vs. control group
in both studies. An additional genome-wide study investigating
the DNAmethylation in both the cerebellum and occipital cortex
found no significant changes between the control and autism
groups, suggesting that the effects in the brain are region-specific
(Ginsberg et al., 2012). Overall, these findings corroborate the
aforementioned gene-specific studies, further reinforcing the
evidence for an involvement of epigenetics in the etiology of ASD.
In addition, they highlight the brain-area specificity of epigenetic
signature, pinpointing the forebrain as one of the brain regions
more liable to environmental insults.
AUTISM AND EPIGENETIC REGULATION
OF IMMUNE GENES AND IMMUNE CELLS
There is converging evidence that the epigenetic regulation of the
immune system may be involved in the etiology of ASD. First,
as mentioned above, hypomethylated CpGs detected in frontal
cortex of autistic individuals were enriched in genes involved in
immune response (Nardone et al., 2014). The genes associated to
those CpGs displayed a significant increase in their transcription:
of particular interest were C1qA, C3, TNF-alpha, and other
transcription factors that are known to be essential in the
development of the microglia. These findings correlate very well
with genome-wide transcriptomic studies that demonstrated an
increased expression of microglia and innate immune response-
related genes in the brain of individuals with autism (Voineagu
et al., 2011; Gupta et al., 2014). Therefore, there is evidence for
dysregulation of the immune response in the autism brain at both
the level of gene transcription and DNA methylation.
Mouse studies have demonstrated that the malfunctioning of
the epigenetic machinery, specifically in microglia cells, can cause
autistic-like behavior. Much of this evidence stems from studies
on Rett Syndrome and the MECP2 gene. As aforementioned,
MeCP2 binds methylated CG sites and contributes to gene
transcription regulation. A major study demonstrated that a Rett
Syndrome-like phenotype, present in microglia-specific MECP2
KO mice, could be reversed by replenishing the MECP2 KO
with wild type microglia (Derecki et al., 2012). Furthermore,
Maezawa et al. proved that deletion of MECP2 in microglia
induced dysregulation of extracellular glutamate levels and
neuronal dendrites (Maezawa and Jin, 2010). In a follow-up
study, the same research group demonstrated that inhibition of
the interaction betweenmicroglia and neurons in theMECP2KO
mice can attenuate many of the Rett Syndrome-like behavioral
manifestations (Horiuchi et al., 2016). These studies suggest
that MeCP2 influences mouse behavior by regulating epigenetic
machinery in microglia. It is important to note, however, that a
recent study was not able to entirely replicate those main findings
(Wang et al., 2015). So it remains unclear whether microglia is
the main or only one of many factors that play a role in the
etiology of Rett Syndrome. while the exact role of microglia is
not completely defined, there is much evidence to suggest the
epigenetic regulation of microglia plays an important role in the
etiology of ASD.
Although there is sufficient evidence for increased immune
activation in the brains of autistic subjects, immune system genes
are not among those that are often mutated in autism. Therefore,
immune activation is unlikely to be explained by genetic etiology,
but rather via epigenetic machinery. In conclusion, the immune
activation detected in brain and blood samples of autistic subjects
may be due to environmental factors and mediated by epigenetic
mechanisms.
CAN THE PRENATAL ENVIRONMENT
INDUCE DNA METHYLATION CHANGES IN
THE OFFSPRING?
The primary question that we aim to address is whether the
epigenetic differences detected in the brain and peripheral
tissues of autism individuals are due to environmental insults
during development, such as MIA. In order to consider this
possibility, wemust first establish the extent to which the prenatal
environment may generally affect the epigenetic machinery.
Multiple human studies have been performed to determine a
link between environmental insults during pregnancy and altered
methylation patterns in the offspring. A well-known example is
the study based on the Dutch Famine Winter, which investigated
the offspring of mothers exposed to famine conditions during
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pregnancy. The offspring displayed dysregulation of DNA
methylation in genomic regions associated to the gene IGF2, an
imprinted gene that has primary roles in metabolism (Heijmans
et al., 2008). This epigenetic alteration was maintained for
several decades after the famine, showing that environmental
insults during pregnancy may have a very longlasting effects
on epigenetic patterning. Similarly, multiple studies have found
dysregulation in DNAmethylation in the cord blood of offspring
from mothers diagnosed with gestational diabetes (Quilter et al.,
2014; Finer et al., 2015). In addition, other environmental cues
that can influence the stress response during pregnancy and the
insurgency ofmaternal depression episodes (Nemoda et al., 2015)
have been associated with DNAmethylation changes in offspring.
Yet some of the most meaningful data came from studies
investigating the effects of maternal smoking. Maternal smoking
during pregnancy has been associated with dysregulation of DNA
methylation in multiple genes in newborns, including NeuroG1
and CNTNAP2, which are known to play a pivotal role in
language development and have been associated with ASD by
several studies (Küpers et al., 2015; Lee et al., 2015; Richmond
et al., 2015). An additional factor that has the potential to
influence the epigenetic machinery is the level of maternal serum
folate during pregnancy. Folic acid deficiency during pregnancy
may be accountable for the occurrence of neurodevelopmental
abnormalities, such as spina bifida. Nowadays folic acid is a
widely-prescribed supplement during pregnancy, and has been
associated with a decreased risk of developing ASD, despite its
mechanism of action not being completely understood (Schmidt
et al., 2012; Surén et al., 2013). Recently, it has been shown that
a mother’s folate level is correlated to differential methylation in
several developmental-related genes in offspring (Joubert et al.,
2016). As such folic acid supplementation may be an additional
environmental factor that regulates epigenetic programming
during development. Together, these human studies provide a
firm basis for the linkage between the in utero environment and
dysregulation of DNA methylation patterning.
COULD MIA BE RESPONSIBLE FOR
EPIGENETIC DYSREGULATION IN ASD?
Considering the association of both MIA and epigenetic
dysregulation in autism, immune activation in pregnant mothers
may be instrumental in epigenetic dysregulation and the
downstream behavioral phenotypes observed in autistic children.
In support of this idea, recent animal studies have proven that
MIA can alter epigenetic patterns associated to autism-candidate
genes in the offspring brain (Table 1). An initial study found
that MIA induced a decrease in global histone acetylation levels
in the cortex of juvenile offspring. Also detected were gene-
specific changes of histone acetylation at several neuron-related
gene promoters in both the cortex and hippocampus of juvenile
offspring (Tang et al., 2013). Although these epigenetic patterns
did not survive till adulthood, it is conceivable that their transient
effect on gene transcription may cause permanent effects that
persist into adulthood. The authors did in fact show that adult
offspring displayed abnormalities in exploratory behavior. A
separate study found only few changes in histone acetylation
levels in adult mice after MIA (Connor et al., 2012). So it
appears most likely that changes in histone modifications occur
mainly during developmental stages and are no longer present
in adulthood. Preliminary studies have recently been performed
in order to investigate the relationship between MIA and DNA
methylation in the brain of offspring. The injection of pregnant
mice with Poly I:C induced a decrease of DNA methylation of
CpGs associated to MECP2 and LINE-1 in the hypothalamus of
the newborns (Basil et al., 2014). While the biological meaning
of dysregulation in MECP2 is well understood, the implications
of LINE-1 dysregulation remainunclear, especially in light of
the fact that LINE-1 methylation levels are often employed
to detect any variation in global DNA methylation. Further
studies are necessary to fully understand if a decrease in DNA
methylation detected in LINE-1 can be indicative of genome-
wide hypomethylation after MIA. In a more recent study,
offspring of Poly I:C treated mothers displayed hypermethylation
at the promoter of Glutamic Acid Decarboxylase 1 (GAD1) and
Glutamic Acid Decarboxylase 2 (GAD2) genes in the prefrontal
cortex (Labouesse et al., 2015). An increase in DNA methylation
levels was associated with augmented MeCP2 binding and
lower gene expression. GAD1 and GAD2 are responsible for
the production of the inhibitory neurotransmitter Gamma-
Amino Butyric acid (GABA) from its precursor Glutamate.
Downregulation of the GABAergic system has been characterized
extensively in both autistic children and animal models. Levels of
GABA and its receptors have been found to be downregulated
in the cortex of individuals with autism (Harada et al., 2011;
Crider et al., 2014), and pharmacological activation of GABA
receptors improved social behavior in the BTBR autism mouse
model (Han et al., 2014). Therefore, the link between MIA
and regulation of GABAergic gene-expression operated by DNA
methylation, can represent a possible mechanism leading toward
GABAergic dysfunction in ASD. In summary, animal studies
have provided evidence that MIA induces long term changes in
DNA methylation patterns in the brain of offspring.
Although there is an extreme complexity in conducting
such studies, there is a need for a human investigation
of the relationship between MIA and epigenetics in young
children. However, other environmental factors that have
been associated with autism—and are known to affect the
epigenetic machinery—can also regulate the maternal immune
response during pregnancy. For example, as mentioned earlier,
gestational diabetes has been associated with ASD, and has
been correlated with increased immune activation in the mother
and dysregulated placental DNA methylation. Therefore, it is
plausible that environmental cues such as gestational diabetes can
affect epigenetics modulating the activation of immune system.
MECHANISMS THROUGH WHICH THE
IMMUNE RESPONSE MAY AFFECT
EPIGENETIC PATTERNING
If immune system activation leads to epigenetic dysregulation
seen in autism, there should be a direct molecular mechanism
Frontiers in Neuroscience | www.frontiersin.org 5 July 2016 | Volume 10 | Article 329
Nardone and Elliott Immunity and Epigenetics in Autism
that links the two phenomena. Animal studies have focused
on determining the specific immune factors that might be
responsible for the MIA-induced autism phenotype. Smith
et al. showed the inhibition of the maternal IL-6 mediated
pathway attenuates the MIA-induced autism behavior in
offspring (Smith et al., 2007). Maternal IL-6 was directly
responsible for MIA-induced gene transcription changes in the
offspring frontal cortex. In addition, it has been previously
demonstrated that IL-6 is transferred across the human placenta
(Zaretsky et al., 2004), which suggests that maternal IL-6 could
directly affect the development of the fetal brain. Multiple
studies have independently determined that IL-6 can activate
DNA methyltransferase 1 (DNMT1), thus providing a direct
interaction between MIA and epigenetic regulation. IL-6 induces
the nuclear translocation of DNMT1 through AKT-dependent
phosphorylation of a nuclear location sequence on the DNMT1
protein (Hodge et al., 2007). IL-6 triggers the DNMT1-mediated
hypermethylation at specific promoters in cancer cell lines, that
in turn increases the cellular growth rate along with other
oncogenic properties. While these effects were witnessed in
cancer cells, it is likely that IL-6 can regulate DNMT1 in other
cell types such as brain cells, particularly during development.
DNMT1 is considered a maintenance methyltransferase, which
functions mostly to maintain methylation patterns during
cellular proliferation. As such, it is most likely that IL-6-induced
DNMT1 activation would have effects during neurogenesis,
which takes place mostly during developmental time periods,
such as in utero. Therefore, there may be a direct interaction
between IL-6 and epigenetic machinery, which in turn can
regulate gene expression after MIA. A recent study has found
that IL-17 activation is also mandatory for an MIA-induced
autism-like phenotype in mice (Choi et al., 2016). In fact, it
was demonstrated that IL-17-producing T-cells were recruited
to the placenta and IL-17 was activated in the developing
neocortex. Possible effects of IL-17 on epigenetic machinery have
not been extensively studied, however, one study did find that
IL-17 inhibits HDAC activity, most likely through PI-3Kinase
signaling pathway (Zijlstra et al., 2012). So while IL-6 may
directly mediate changes in DNA methylation, IL-17 may affect
histone acetylation. Further investigations are still required to
really understand if the effect of prenatal IL-6 and IL-17 on
offspring behavior is mediated through epigenetic mechanisms.
The mechanism by which most cytokines are likely to
influence epigenetic patterns is through regulation of signal
transduction pathways that activate epigenetic enzymes or
recruit chromatin regulators to the DNA. Two of the main
signal transduction pathways that are activated by cytokines
are JAK/STAT and MAPK/ERK signaling pathways (Heinrich
et al., 2003). STAT proteins act as transcription factors, and also
mediate the remodeling of histone acetylation at STAT-binding
sites (Wei et al., 2010). The MAP/ERK signaling pathway affects
multiple epigenetic modulators, such as CREB. The activation
of CREB by phosphorylation involves the recruitment of a
chromatin modifying complex, the histone acetyltransferase CBP
to the chromatin (Ogryzko et al., 1996). CREB has been shown to
be activated by various interleukins, including IL-18 (Zhou et al.,
2014) and IL-6 (Melemedjian et al., 2014). While we have just
shown that two specific pathways through which IL-6 and IL-
17 may affect epigenetic enzymes, it is probable that cytokines
or other soluble mediators of the immune response can actually
affect epigenetic marks through multiple signaling pathways.
THE MICROBIOME AS A POSSIBLE
MODULATOR BETWEEN MIA AND THE
AUTISM PHENOTYPE
Of notable interest to neuroscience in general, and to
neurodevelopment in particular, is the contribution of the
microbiome to human health. The population of bacteria that
lives in symbiosis with the human body, collectively known
as the microbiome, has recently been shown to influence
behavior (Cryan and Dinan, 2012). Of particular interest to
this review, the microbiome conducts a very tight crosstalk
with the host immune system (Kau et al., 2011). In fact,
the microbiome population affects the activity of the immune
system, and vice-versa. In addition, recent studies have found
that autistic individuals own a distinct microbiome signature
compared to non-autistic individuals and even to individuals
who were previously diagnosed with Pervasive Developmental
Disorder (De Angelis et al., 2013). A recent rodent study
suggested that MIA-induced autism phenotypes are caused by
an alteration in the number and composition of the wild type
mouse microbiota; in particular B. fragilis played a fundamental
role (Hsiao et al., 2013). Hsiao et al. found that B. fragilis
specifically affects repetitive behaviors while not having any
influence on social behaviors. Therefore, MIA may affect the
development of ASD by partially regulating the microbiome
composition, even though the molecular mechanisms by which
the microbiome may trigger ASD-related behavior are still
unknown.
One of the main metabolic products of the microbiome is
short-chained fatty acids, including sodium butyrate. Sodium
butyrate is well characterized as a histone deacetylase (HDAC)
inhibitor (Davie, 2003), and can easily cross the blood-brain
barrier. Therefore, sodium butyrate could represent a direct link
between the microbiome and epigenetic machinery in the brain.
In a previous study it was found that sodium butyrate can
also attenuate autism-like behavior in the BTBR mice, which
is another autism mouse model often used in pharmacological
studies (Kratsman et al., 2015). It was also shown that sodium
butyrate specifically affected the transcription of genes involved
in the excitation/inhibition balance and GABAergic signaling in
mouse prefrontal cortex. So aside from being a common bacterial
metabolite, sodium butyrate, is also a very efficient epigenetic
modulator that can possibly influence processes that rely on a
subtle balance of neurotransmitters. Further studies are needed to
understand if immune regulation of the microbiome can induce
epigenetic changes in the brain throughmodulation of fatty acids.
CONCLUSIONS
Separate studies have implicated both immune and epigenetic
dysregulation in the etiology of ASD. We set out to review
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the evidence indicating that the two phenomena are not
independent, and that there could actually be a causal
relationship between them. This relationship may have different
aspects including immune activation-induced alterations
in epigenetic patterns in the fetus brain, and epigenetic
regulation of immune cells and immune-related genes in
the brain. As was pointed out early in this discussion, the
development of ASD is a multifactorial process and it is
therefore possible that a genetic predisposition increases the
likelihood of developing ASD after MIA. In support of this
statement, one study found that MIA induced a phenotype
characterized by strong social impairment specifically in
mice overexpressing a double negative form of DISC1 (Ibi
et al., 2010), a gene strongly associated to Schizophrenia
and ASD (Ishizuka et al., 2006; Crepel et al., 2010; Zheng
et al., 2011; Turner et al., 2016). In addition, a recent study
found that autistic individuals who bear both CNVs and
a history of MIA displayed more severe social deficits and
repetitive behaviors (Mazina et al., 2015). This means MIA-
induced epigenetic changes and genetic susceptibility are likely
required to interact to promote autistic behavior. The study,
by means of a simplistic example of GxE interaction, puts
forth a two-hit model that combines the genetic makeup,
as predisposing factor, and environmental cues, as trigger,
for explaining the etiology of complex diseases, such in
psychiatry.
There are many follow-up studies that are needed to further
establish and understand the model of MIA-induced epigenetic
changes in the etiology of ASD. In particular, studies are needed
that look at the epigenetic studies of children whose mother’s
experienced MIA during pregnancy. In addition, it is necessary
to understand why GABAergic genes seem to be particularly
susceptible to MIA and to epigenetic modulation in the brain.
Looking to the future, these studies may lead to a more integrated
model of ASD biology and etiology, which will help determine
the exact relationships between immune response activation
and epigenetic regulation, and how they lead to specific autism
phenotypes.
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